Oral erosions and petechiae during SARS‐CoV‐2 infection

Abstract

An increasing number of reports have been written regarding cutaneous manifestations during the coronavirus disease-2019 (COVID-19),1-3 though knowledge of the possible oral manifestations is still poor. This may be due to a lack of intraoral examinations, which may be caused by limited availability of the recommended protective measures and the use of telemedical consultations for SARS-CoV-2 infections. We describe a patient presenting with cutaneous and oral lesions associated with a SARS-CoV-2 infection. A previously healthy 19-year-old woman presented to the Emergency Department with a seven-day history of intermittent fever and sore throat. She had started taking oral cefixime (400 mg per day) 3 days earlier. She also reported a sudden onset of fatigue, hyposmia, and asymptomatic cutaneous and oropharyngeal lesions that started 2 days before admission. On admission, she was afebrile and her vital signs (blood pressure, beats/minute, oxygen saturation) were normal. Physical examination revealed erythematous macules, papules and petechiae on the lower extremities (Figure 1A); erosions, ulcerations, and blood crusts on the inner surface of the lips (Figure 1B) and palatal and gingival petechiae. Chest radiograph and pulmonary ultrasound were normal. A complete blood cell count revealed increased white cells (12 000/mm3, 60% of lymphocytes), aspartate aminotransferase (200 U/L), alanine aminotransferase (140 U/L), lactic dehydrogenase (LDH) (300 mU/mL) and severe thrombocytopenia (platelet count 2000/mm3). Hemoglobin and C-reactive protein levels were normal. Real-time reverse transcriptase–polymerase chain reaction (PCR) from a nasopharyngeal swab was positive for SARS-CoV-2. Antibiotic therapy was discontinued and intravenous immune globulins (400 mg/kg) and methylprednisolone (1 mg/kg) was administered for 5 days. On day 5, the systemic symptoms regressed, though some maculopapular lesions were still present on the legs; the platelet count had increased to 98 000/mm3, and aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase returned to normal ranges. On day 10, the complete blood count was normal (white cells 9000/mm3 with 40% of lymphocytes; platelet count 152,000/mm3) and skin and mucosal lesions disappeared. In the literature, the prevalence of cutaneous findings in SARS-CoV-2 patients ranges from 0,2%1 to 20,4%.2 Skin lesions are heterogeneous and divided into acral erythematous-edematous chilblain-like lesions, maculopapular, vesicular and urticarial eruptions.3 Petechial eruptions are sporadically reported,4 while oropharyngeal lesions have been described in only seven patients to date (Table 1).5-8 They were all adult patients (mean age 57 years), often affected by diabetes and hypertension, presenting with painful oropharyngeal lesions in the form of ulcers (5 cases),5, 6, 8 blisters and gingivitis (1 case),5 palatal petechiae, erythema and pustules (1 case).7 Histological analysis, performed in three cases revealed inflammatory infiltrates and focal necrosis-hemorrhages in the lamina propria, and in one case, small vessel obliteration with thrombi. In these three cases, infections with herpes simplex virus (HSV)1/2 were excluded through in-situ hybridization and PCR on the lesion tissue.6, 8 Compared to the previously reported cases,5-8 our patient was younger and without comorbidities. Notably, the oral lesions in our patient were painless, heterogeneous in morphology, and associated with severe thrombocytopenia that was probably of crucial importance in determining the onset of her cutaneous and mucosal petechiae. Conversely, the oral erosions might have been caused by direct viral vascular and mucosal damage, as SARS-CoV-2 uses the host protein angiotensin-converting enzyme-2 (largely expressed in vessels, nasal and oral mucosa) to gain intracellular entry.1 Mild thrombocytopenia (50 000–150 000 platelets/mm3) is commonly found in viral infections9 and has been described in 36% of COVID-19 patients.1 Its pathogenesis is multifactorial: the hyper-inflammatory state and cytokine storm induced by the viral infection induces a prothrombotic state with endothelial and platelet activation and consumption. The reduced platelet production may be influenced by a direct viral insult to the bone marrow10 and the use of antibiotics, antivirals, and other agents may further reduce the platelet count.11 Therefore, we ascribed, at least for the petechial component, the cutaneous and mucosal lesions of our patient to her severe thrombocytopenia, triggered by the SARS-CoV-2 infection and potentially worsened by the cefixime treatment. Indeed, drug-induced thrombocytopenia by cephalosporins has already been described.11, 12 Our case deserves attention for several reasons: the severe thrombocytopenia, uncommon until the later stages of COVID-19,10 the maculopapular-petechial eruption, a rarely reported cutaneous manifestation, and, importantly, the presence of erosions and blood crusts on the inner mucosa of the lips and gingival-oropharyngeal petechiae. Such mucosal lesions have never been described during a SARS-CoV-2 infection. In conclusion, the intraoral examination should always be performed in patients with suspected or confirmed SARS-CoV-2 infection. Detection of mucosal lesions, with or without cutaneous manifestations, could represent a sign of potentially life-threatening conditions such as severe thrombocytopenia, even in patients with apparently mild COVID-19. The authors declare that there are no conflict of interests.

Topics & Concepts